Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes among selected centres in North America and Europe: an international multicentre collaboration.

#BladderCancer #blcsm radical cystectomy robotic time trend

Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
Oct 2019
Historique:
pubmed: 6 5 2019
medline: 6 5 2019
entrez: 6 5 2019
Statut: ppublish

Résumé

To compare trends in the use of robot-assisted radical cystectomy (RARC) and changes over time in peri-operative outcomes in selected North American and European centres. We conducted a retrospective evaluation of 2401 patients treated with open radical cystectomy (ORC) or RARC for bladder cancer at 12 centres in North America and Europe between 2006 and 2018. We used the Kruskal-Wallis and chi-squared test to evaluate differences between continuous and categorical variables. Overall, 49.5% of patients underwent RARC and 51.5% ORC. RARC became the most commonly performed procedure in contemporary patients, with an increase from 29% in 2006-2008 to 54% in 2015-2018 (P < 0.001). In the North American centres the use of RARC was higher than that of ORC from 2006, and remained stable over time, whereas in the European centres its use increased exponentially from 2% to 50%. In both groups patients who underwent RARC had less advanced T stages (P < 0.001), lower American Society of Anesthesiologists scores (P < 0.05), lower blood loss (P = 0.001) and shorter length of hospital stay (P < 0.05). No differences were found in early complications. Early readmission and re-operation rates were worse for patients treated with RARC in the European centres; however, when contemporary patients only were considered, the statistical significance was lost. The present study shows that the use of RARC has constantly increased since its introduction, overtaking ORC in the most contemporary series. While RARC was more frequently performed than ORC since its introduction in the North American centres and its use remained substantially stable over time, its use increased exponentially in the European centres. The different trends in use of RARC/ORC and changes over time in peri-operative outcomes between the North American and European centres can be attributed to the earlier introduction and spread of RARC in the former compared with the latter.

Identifiants

pubmed: 31055865
doi: 10.1111/bju.14791
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

656-664

Informations de copyright

© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.

Références

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017; 71: 96-108
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30
Alfred Witjes J, Lebret T, Compérat EM et al. Updated 2016 EAU guidelines on Muscle-invasive and metastatic bladder cancer. Eur Urol 2017; 71: 462-75
Collins JW, Patel H, Adding C et al. Enhanced recovery after robot-assisted radical cystectomy: EAU robotic urology section scientific working group consensus view. Eur Urol 2016; 70: 649-60
Moschini M, Simone G, Stenzl A, Gill IS, Catto J. Critical review of outcomes from radical cystectomy: can complications from radical cystectomy be reduced by surgical volume and robotic surgery? Eur Urol Focus 2016; 2: 19-29
Bochner BH, Dalbagni G, Sjoberg DD et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur Urol 2015; 67: 1042-50
Hanna N, Leow JJ, Sun M et al. Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol 2018; 36: 88. e1-88.e9
Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol 2010; 57: 196-201
Hussein AA, May PR, Jing Z et al. Outcomes of intracorporeal urinary diversion after robot-assisted radical cystectomy: results from the international robotic cystectomy consortium. J Urol 2018; 199: 1302-11
Challacombe BJ, Bochner BH, Dasgupta P et al. The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol 2011; 60: 767-75
Yu H, Hevelone ND, Lipsitz SR et al. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol 2012; 61: 1239-44
Styn NR, Montgomery JS, Wood DP et al. Matched comparison of robotic-assisted and open radical cystectomy. Urology 2012; 79: 1303-8
Ng CK, Kauffman EC, Lee M-M et al. A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol 2010; 57: 274-81
Martin AD, Nunez RN, Pacelli A et al. Robot-assisted radical cystectomy: intermediate survival results at a mean follow-up of 25 months. BJU Int 2010; 105: 1706-9
Parekh DJ, Reis IM, Castle EP et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 2018; 391: 2525-36
AJCC Cancer Staging Manual| Frederick L, Greene | Springer n.d. Available at: https://www.springer.com/us/book/9781475736564. Accessed October 2018.
Chang SS, Bochner BH, Chou R et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol 2017; 198: 552-9
Menon M, Hemal AK, Tewari A et al. Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion. BJU Int 2003; 92: 232-6
Soria F, Moschini M, D'andrea D et al. Comparative effectiveness in perioperative outcomes of robotic versus open radical cystectomy: results from a multicenter contemporary retrospective cohort study. Eur Urol Focus 2018. [Epub ahead of print]. https://doi.org/10.1016/j.euf.2018.11.002.
Hu JC, Chughtai B, O'Malley P et al. Perioperative outcomes, health care costs, and survival after robotic-assisted versus open radical cystectomy: a national comparative effectiveness study. Eur Urol 2016; 70: 195-202
Linder BJ, Frank I, Cheville JC et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013; 63: 839-45
Moschini M, Bianchi M, Gandaglia G et al. The impact of perioperative blood transfusion on survival of bladder cancer patients submitted to radical cystectomy: role of anemia status. Eur Urol Focus 2016; 2: 86-91
Tan WS, Khetrapal P, Tan WP, Rodney S, Chau M, Kelly JD. Robotic assisted radical cystectomy with extracorporeal urinary diversion does not show a benefit over open radical cystectomy: a systematic review and meta-analysis of randomised controlled trials. PLoS ONE 2016; 11: e0166221

Auteurs

Stefania Zamboni (S)

Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.
Urology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili, University of Brescia, Vienna, Austria.

Francesco Soria (F)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Division of Urology, Department of Surgical Sciences, University of Studies of Torino, Turin, Italy.

Romain Mathieu (R)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Department of Urology, Rennes University Hospital, Rennes, France.

Evanguelos Xylinas (E)

Department of Urology Bichat Hospital, Paris Descartes University, Paris, France.

Mohammad Abufaraj (M)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.

David D Andrea (D)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.

Wei Shen Tan (WS)

Division of Surgery and Intervention Science, University College London, London, UK.
Department of Urology, University College London Hospital, London, UK.
Department of Uro-oncology, University College London Hospital NHS Foundation Trust, London, UK.

John D Kelly (JD)

Division of Surgery and Intervention Science, University College London, London, UK.
Department of Urology, University College London Hospital, London, UK.
Department of Uro-oncology, University College London Hospital NHS Foundation Trust, London, UK.

Giuseppe Simone (G)

Department of Urology, "ReginaElena" National Cancer Institute, Rome, Italy.

Michele Gallucci (M)

Department of Urology, "ReginaElena" National Cancer Institute, Rome, Italy.

Anoop Meraney (A)

Urology Division, Hartford Healthcare Medical Group, Hartford, CT, USA.

Suprita Krishna (S)

Department of Urology, University of Minnesota, Minneapolis, MN, USA.

Badrinath R Konety (BR)

Department of Urology, University of Minnesota, Minneapolis, MN, USA.

Alessandro Antonelli (A)

Urology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili, University of Brescia, Vienna, Austria.

Claudio Simeone (C)

Urology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili, University of Brescia, Vienna, Austria.

Philipp Baumeister (P)

Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.

Agostino Mattei (A)

Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.

Alberto Briganti (A)

Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy.

Andrea Gallina (A)

Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy.

Francesco Montorsi (F)

Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy.

Michael Rink (M)

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Atiqullah Aziz (A)

Department of Urology, University Medical Center Rostock, Rostock, Germany.

Pierre I Karakiewicz (PI)

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada.

Morgan Rouprêt (M)

GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.

Anthony Koupparis (A)

Bristol Urological Institute, North Bristol NHS Trust, Southmead Hospital, Bristol, UK.

Douglas S Scherr (DS)

Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.

Guillaume Ploussard (G)

Department of Urology, La croix du sud, Toulouse, France.

Prasanna Sooriakumaran (P)

Department of Uro-oncology, University College London Hospital NHS Foundation Trust, London, UK.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Shahrokh F Shariat (SF)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Marco Moschini (M)

Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.

Classifications MeSH